Trial · NCT00779142
Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies
NCT00779142, Not applicable, Terminated, Wake Forest University; results first posted 2014-06-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies. Trials, record NCT00779142. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00779142
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies
- NCT number
- NCT00779142
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 2 participants, actual
- Lead sponsor
- Wake Forest University
- Conditions
- Diabetic Macular Edema
- Interventions
- Methotrexate intravenous 25mg/ml
- First posted
- 2008-10-24
- Last updated
- 2018-01-23
- Results first posted
- 2014-06-30
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 30% Decrease in One Subfield Thickness on Optical Coherence Tomography (OCT) 4 Weeks After the Last Intraocular Injection | 4 weeks | |
| Secondary | Number of Participants With Increase in Visual Acuity (VA) Two Lines or More at the End of One Month After the Last Intraocular Injection | 1 month | |
| Secondary | Secondary Would be Significant Clinical Improvement (Judged at the Slit Lamp Exam Using a 90D Lens) in Macular Edema at the End of One Month After the Last Intraocular Injection. | 1 month |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | 30% Decrease in One Subfield Thickness on Optical Coherence Tomography (OCT) 4 Weeks After the Last Intraocular Injection | 4 weeks | participants | NUMBER | |
| SECONDARY | Number of Participants With Increase in Visual Acuity (VA) Two Lines or More at the End of One Month After the Last Intraocular Injection | 1 month | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Secondary Would be Significant Clinical Improvement (Judged at the Slit Lamp Exam Using a 90D Lens) in Macular Edema at the End of One Month After the Last Intraocular Injection. | 1 month | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 30% Decrease in One Subfield Thickness on Optical Coherence Tomography (OCT) 4 Weeks After the Last Intraocular Injection | Methotrexate 25mg/ml | 2 | participants | ||
| Number of Participants With Increase in Visual Acuity (VA) Two Lines or More at the End of One Month After the Last Intraocular Injection | Methotrexate 25mg/ml | 1 | Participants | ||
| Secondary Would be Significant Clinical Improvement (Judged at the Slit Lamp Exam Using a 90D Lens) in Macular Edema at the End of One Month After the Last Intraocular Injection. | Methotrexate 25mg/ml | 1 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Methotrexate 25mg/ml | 5 | |
| Overall Study | COMPLETED | Methotrexate 25mg/ml | 2 | |
| Overall Study | NOT COMPLETED | Methotrexate 25mg/ml | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Methotrexate 25mg/ml | ||
| Total, other adverse events | Methotrexate 25mg/ml | 0 | 5 |
| Total, serious adverse events | Methotrexate 25mg/ml | 0 | 5 |
Source ClinicalTrials.gov
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00779142
GET https://conductscience.org/api/trials/v1/NCT00779142/registered